Sheldon S. Leung

543 total citations
21 papers, 368 citations indexed

About

Sheldon S. Leung is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Sheldon S. Leung has authored 21 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in Sheldon S. Leung's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Biosimilars and Bioanalytical Methods (5 papers) and Virus-based gene therapy research (4 papers). Sheldon S. Leung is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Biosimilars and Bioanalytical Methods (5 papers) and Virus-based gene therapy research (4 papers). Sheldon S. Leung collaborates with scholars based in United States, Canada and Sweden. Sheldon S. Leung's co-authors include Donna J. Koslowsky, Alison Joyce, Takashi Kishimoto, Mengmeng Wang, Lloyd Johnston, Alan Kivitz, Christopher Roy, Petr O. Ilyinskii, Wesley DeHaan and Xin Xu and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Science Advances.

In The Last Decade

Sheldon S. Leung

20 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheldon S. Leung United States 12 211 94 66 65 55 21 368
Taiming Li China 15 300 1.4× 271 2.9× 34 0.5× 103 1.6× 45 0.8× 44 562
Anna Marei Eichhoff Germany 7 142 0.7× 88 0.9× 91 1.4× 51 0.8× 85 1.5× 7 402
Ellen Bleck Germany 13 108 0.5× 117 1.2× 52 0.8× 29 0.4× 36 0.7× 25 405
JoAnn S. Roberts United States 11 195 0.9× 68 0.7× 124 1.9× 17 0.3× 52 0.9× 14 585
H. A. Daniel Lagassé United States 8 134 0.6× 73 0.8× 32 0.5× 18 0.3× 22 0.4× 13 301
Masaki Kuwabara Japan 10 117 0.6× 71 0.8× 25 0.4× 34 0.5× 24 0.4× 23 370
Fabian D. Arditti Israel 8 292 1.4× 66 0.7× 22 0.3× 32 0.5× 29 0.5× 16 451
Maria Marotta Italy 15 246 1.2× 46 0.5× 63 1.0× 82 1.3× 61 1.1× 30 594
Elizabeth Elder United Kingdom 12 109 0.5× 77 0.8× 26 0.4× 38 0.6× 188 3.4× 15 369

Countries citing papers authored by Sheldon S. Leung

Since Specialization
Citations

This map shows the geographic impact of Sheldon S. Leung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheldon S. Leung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheldon S. Leung more than expected).

Fields of papers citing papers by Sheldon S. Leung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheldon S. Leung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheldon S. Leung. The network helps show where Sheldon S. Leung may publish in the future.

Co-authorship network of co-authors of Sheldon S. Leung

This figure shows the co-authorship network connecting the top 25 collaborators of Sheldon S. Leung. A scholar is included among the top collaborators of Sheldon S. Leung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheldon S. Leung. Sheldon S. Leung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ilyinskii, Petr O., et al.. (2023). Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents. PNAS Nexus. 2(11). pgad394–pgad394. 10 indexed citations
2.
Kivitz, Alan, Wesley DeHaan, Justin Park, et al.. (2023). Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110). Rheumatology and Therapy. 10(4). 825–847. 16 indexed citations
3.
Baraf, Herbert S. B., Alan Kivitz, Sheldon S. Leung, et al.. (2023). LB0002 SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES. Annals of the Rheumatic Diseases. 82. 200–201. 3 indexed citations
4.
Kishimoto, Takashi, Christopher Roy, Fen-Ni Fu, et al.. (2023). Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease. Journal of Autoimmunity. 140. 103125–103125. 15 indexed citations
5.
Kivitz, Alan, et al.. (2022). Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nature Communications. 13(1). 272–272. 40 indexed citations
6.
7.
Ilyinskii, Petr O., Christopher Roy, Sheldon S. Leung, et al.. (2021). ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia. Molecular Therapy — Methods & Clinical Development. 22. 279–292. 27 indexed citations
8.
Leung, Sheldon S., et al.. (2019). Multiplexed Immunoassay Approach to Characterize Antidrug Antibody Like Specific Reactivity. Bioanalysis. 11(8). 703–712. 1 indexed citations
9.
Ma, Mark, Kelly Colletti, Tong‐Yuan Yang, et al.. (2019). Bioanalytical Challenges and Unique Considerations to Support Pharmacokinetic Characterization of Bispecific Biotherapeutics. Bioanalysis. 11(5). 427–435. 5 indexed citations
10.
Fan, Yao‐Yun, Lindsay B. Avery, Mengmeng Wang, et al.. (2016). Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. mAbs. 8(5). 848–853. 22 indexed citations
11.
Joyce, Alison, et al.. (2014). One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics. Pharmaceutical Research. 31(7). 1823–1833. 42 indexed citations
12.
Gorovits, Boris, et al.. (2014). Protein-Based Matrix Interferences in Ligand-Binding Assays. Bioanalysis. 6(8). 1131–1140. 19 indexed citations
13.
Joyce, Alison & Sheldon S. Leung. (2013). Use of response surface methods and path of steepest ascent to optimize ligand-binding assay sensitivity. Journal of Immunological Methods. 392(1-2). 12–23. 24 indexed citations
14.
Vugmeyster, Yulia, et al.. (2013). Pharmacokinetics of anti-IL17A and anti-IL22 peptide–antibody bispecific genetic fusions in mice. International Immunopharmacology. 18(2). 225–227. 7 indexed citations
15.
16.
Neubert, Hendrik, Scott Fountain, Lindsay King, et al.. (2012). Tissue Bioanalysis of Biotherapeutics And Drug Targets to Support Pk/Pd. Bioanalysis. 4(21). 2589–2604. 26 indexed citations
17.
Hill, Sharon R., Sheldon S. Leung, Nada Quercia, et al.. (2001). Ikirara Insertions Reveal Five New Anopheles gambiae Transposable Elements in Islands of Repetitious Sequence. Journal of Molecular Evolution. 52(3). 215–231. 11 indexed citations
18.
Leung, Sheldon S.. (2001). RNA editing in Trypanosoma brucei: characterization of gRNA U-tail interactions with partially edited mRNA substrates. Nucleic Acids Research. 29(3). 703–709. 16 indexed citations
19.
Leung, Sheldon S. & Donna J. Koslowsky. (1999). Mapping contacts between gRNA and mRNA in trypanosome RNA editing. Nucleic Acids Research. 27(3). 778–787. 38 indexed citations
20.
Leung, Sheldon S. & Patricia Romans. (1998). Excisions of the Ikirar1 transposon in an Anopheles gambiae cell line. Insect Molecular Biology. 7(3). 241–248. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taiming Li Breakdown of academic impact, for papers by Anna Marei Eichhoff Breakdown of academic impact, for papers by Ellen Bleck Breakdown of academic impact, for papers by JoAnn S. Roberts Breakdown of academic impact, for papers by H. A. Daniel Lagassé Breakdown of academic impact, for papers by Masaki Kuwabara Breakdown of academic impact, for papers by Fabian D. Arditti Breakdown of academic impact, for papers by Maria Marotta Breakdown of academic impact, for papers by Elizabeth Elder
Rankless by CCL
2026